LONG BEACH, Calif. — Re-Vana Therapeutics is collaborating with Boehringer Ingelheim to develop extended-release therapies for ophthalmic diseases, according to a press release.
At the American Society of Retina Specialists annual meeting, Re-Vana CEO Michael O’Rourke told Healio that the relationship will include up to three target-specific therapeutics from Boehringer Ingelheim to match with Re-Vana’s technology.
{{VIDEO}}
“The goal here is to have extended release of therapeutics and to reduce the frequency of intravitreal injections, which have been common in the